SEARCH

SEARCH BY CITATION

References

  • 1
    Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735739.
  • 2
    Pettaway CA, Freeman C, Helderman JH, Stastny P. Kidney transplant recipients with long incubation-positive antiglobulin-negative T cell crossmatches. Transplantation 1987; 44: 529533.
  • 3
    Talbot D, Givan AL, Shenton BK, Stratton A, Proud G, Taylor RM. The relevance of a more sensitive crossmatch assay to renal transplantation. Transplantation 1989; 47: 552555.
  • 4
    Kao KJ, Scornik JC, Small SJ. Enzyme-linked immunoassay for anti-HLA antibodies–an alternative to panel studies by lymphocytotoxicity. Transplantation 1993; 55: 192196.
  • 5
    Zachary AA, Ratner LE, Graziani JA, Lucas DP, Delaney NL, Leffell MS. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: II. Clinical relevance. Hum Immunol 2001; 62: 236246.
  • 6
    Lefaucheur C, Nochy D, Hill GS et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7: 832841.
  • 7
    Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346351.
  • 8
    Glotz D, Haymann JP, Niaudet P, Lang P, Druet P, Bariety J. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant Proc 1995; 27: 10381039.
  • 9
    Glotz D, Antoine C, Julia P et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758760.
  • 10
    Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713723.
  • 11
    Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708714.
  • 12
    Cardella CJ, Falk JA, Nicholson MJ, Harding M, Cook GT. Successful renal transplantation in patients with T-cell reactivity to donor. Lancet 1982; 2: 12401243.
  • 13
    Matas AJ, Nehlsen-Cannarella S, Tellis VA, Kuemmel P, Soberman R, Veith FJ. Successful kidney transplantation with current-sera-negative/historical-sera-positive T cell crossmatch. Transplantation 1984; 37: 111112.
  • 14
    Goeken NE. Outcome of renal transplantation following a positive cross-match with historical sera: The ASHI survey. Hum Immunol 1985; 14: 7785.
  • 15
    Sanfilippo F, Vaughn WK, Spees EK, Bollinger RR. Cadaver renal transplantation ignoring peak-reactive sera in patients with markedly decreasing pretransplant sensitization. Transplantation 1984; 38: 119124.
  • 16
    Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3: 14881500.
  • 17
    Pollinger HS, Stegall MD, Gloor JM et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007; 7: 857863.
  • 18
    Ghasemian SR, Light JA, Currier CB et al. The significance of the IgG anti-B-cell crossmatch on renal transplant outcome. Clin Transplant 1997; 11: 485487.
  • 19
    Lobashevsky AL, Senkbeil RW, Shoaf J et al. Specificity of preformed alloantibodies causing B cell positive flow crossmatch in renal transplantation. Clin Transplant 2000; 14: 533542.
  • 20
    Anglicheau D, Loupy A, Suberbielle C et al. Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: A pilot study. Am J Transplant 2007; 7: 11851192.
  • 21
    Karpinski M, Rush D, Jeffery J et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001; 12: 28072814.
  • 22
    Iwaki Y, Cook DJ, Terasaki PI et al. Flow cytometry crossmatching in human cadaver kidney transplantation. Transplant Proc 1987; 19: 764766.
  • 23
    Mahoney RJ, Ault KA, Given SR et al. The flow cytometric crossmatch and early renal transplant loss. Transplantation 1990; 49: 527535.
  • 24
    Kerman RH, Van Buren CT, Lewis RM et al. Improved graft survival for flow cytometry and antihuman globulin crossmatch-negative retransplant recipients. Transplantation 1990; 49: 5256.
  • 25
    Bryan CF, Baier KA, Nelson PW et al. Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Transplantation 1998; 66: 18271832.
  • 26
    Patel AM, Pancoska C, Mulgaonkar S, Weng FL. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007; 7: 23712377.
  • 27
    El Fettouh HA, Cook DJ, Bishay E et al. Association between a positive flow cytometry crossmatch and the development of chronic rejection in primary renal transplantation. Urology 2000; 56: 369372.
  • 28
    Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887895.
  • 29
    Sonnenday CJ, Ratner LE, Zachary AA et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002; 34: 16141616.
  • 30
    Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553562.
  • 31
    Zachary AA, Montgomery RA, Ratner LE et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76: 15191525.
  • 32
    Jordan SC. Management of the highly HLA-sensitized patient: A novel role for intravenous gammaglobulin. Am J Transplant 2002; 2: 691692.
  • 33
    Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 32563262.